Skip to main content
    • Mounjaro

    What Happens When You Stop Taking Mounjaro?

    Stopping Mounjaro: what happens to appetite and weight, what the evidence shows about regain, and how to come off it sensibly. Pharmacist-written UK guide.

    Jimah Alsaai MPharmJimah Alsaai MPharmSuperintendent Pharmacist
    GPhC 2232652     Reviewed September 2026
    Updated July 2026 · 6 min read

    Stopping Mounjaro is a normal question, and one worth thinking about clearly rather than hoping for the best. Here's what actually happens, what the evidence shows, and how to give yourself the best chance of holding on to progress.

    Mounjaro KwikPen in all six strengths, 2.5mg to 15mg
    The Mounjaro KwikPen comes in six strengths, from 2.5mg to 15mg.

    Appetite returns

    Tirzepatide works while it's in your system. Once you stop, appetite suppression fades over the following weeks as the drug clears. Most people notice hunger and food noise returning. This is expected, not a failure of willpower.

    What the evidence says about regain

    Obesity is a chronic, relapsing condition, and the trial evidence reflects that. Withdrawal studies of GLP-1 and dual-agonist therapy consistently show substantial regain of lost weight after stopping, in a similar pattern to stopping antihypertensives and seeing blood pressure rise again. This isn't a reason not to treat. It's a reason to plan.

    There's no withdrawal syndrome

    Stopping isn't dangerous, and there are no withdrawal effects in the pharmacological sense. GI side effects typically settle. If you have type 2 diabetes, blood glucose will need monitoring and stopping should be planned with your prescriber.

    How to come off it more successfully

    • Don't stop abruptly from a high dose if it can be avoided: a gradual step-down gives you time to adapt.
    • Have the habits in place first: protein intake, resistance training, sleep, food environment.
    • Expect appetite to return and plan for it, rather than being ambushed.
    • Keep weighing and monitoring: early regain is far easier to address than late regain.
    • Discuss a maintenance dose. Staying on a lower dose long-term is a legitimate option.

    Reasons people stop

    • Reaching a goal weight.
    • Cost.
    • Side effects.
    • Supply.
    • Pregnancy or planning pregnancy, in which case Mounjaro must be stopped and timing discussed with your prescriber.
    Stopping isn't the end of the story. It's the start of the next phase. Treat maintenance with the same seriousness as treatment, and regain becomes far less likely.

    See also Mounjaro vs Wegovy and Mounjaro weight loss by week.

    When to see your pharmacist or doctor

    • Always discuss stopping with your prescriber first, especially if you have type 2 diabetes or take other glucose-lowering medicines.
    • Stop and seek advice immediately if you become pregnant or are planning pregnancy.
    • If regain is rapid after stopping, arrange review sooner rather than later.
    Urgent help, genuine medicines and the official leaflets

    Frequently asked questions

    Trial evidence consistently shows substantial regain of lost weight after stopping GLP-1 and dual-agonist therapy. Some regain is the norm, and how much depends heavily on the habits and support in place when you stop.

    Not necessarily, but obesity is a chronic condition, and a lower maintenance dose is often more realistic than stopping entirely.

    No. There is no pharmacological withdrawal syndrome. Appetite returns as the drug clears, but stopping itself isn't dangerous.

    Tirzepatide has a half-life of about five days, so it takes several weeks to leave the body; the UK product information advises stopping it at least one month before a planned pregnancy.

    Yes, but restarting usually requires re-titrating from a lower dose to manage side effects. Always under prescriber guidance.

    Keep reading

    Sources · 5Show
    1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022.
    2. SURMOUNT-4 treatment withdrawal study.
    3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384:989-1002.
    4. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553-1564.
    5. Mounjaro Summary of Product Characteristics, electronic medicines compendium.

    Reviewed by Jimah Alsaai MPharm, GPhC 2232652, Superintendent Pharmacist, QuickCare Pharmacy.

    Ready to start?

    Start your free consultation with a GPhC-registered pharmacist.

    Begin consultation